Lowest Price Guaranteed From USD 5,899
Published
November 2022
Slides
90
View Count
2016
Example Insights
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Report Description
Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide. Across the globe, over 6.5 million neurological disorder related deaths are reported annually. Further, according to a report published by the United Nations (UN), close to 1 billion people, globally, suffer from various types of neurological disorders. The growing number of patients suffering from neurodegenerative disorders has imposed a huge burden, in terms of finances as well as resources, on the overall healthcare system. In fact, the annual expenditure associated with neurological disorder care in 2020 was more than USD 655 billion, in the US alone. Given the fact that majority of the current treatment options have proven to be inadequate, especially for axonal degeneration associated neurological disorders, there is a high demand for highly effective therapeutics targeting neurological disorders. Interestingly, Sterile Alpha and toll / Interleukin-1 Receptor Motif-Containing 1 (SARM1), an NADase enzyme, has been found to play a critical role in inducing axonal degeneration, which is a central pathological feature in various neurodegenerative disorders.
Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in this domain have received more than USD 10 million in grants, since 2014, from the various private and public organizations. Additionally, several patents related to SARM1 inhibitors have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 inhibitors market is anticipated to witness substantial growth in the mid to long-term.
The ‘SARM1 Inhibitors Therapeutics Market by Target Indications (Multiple Sclerosis, Peripheral, Central and Ocular Nervous System Disorders, Peripheral Neuropathies, Glaucoma and Amyotrophic Lateral Sclerosis), Type of Molecule (Small Molecules and Biologics), Drug Developers, Drug Candidates and Key Geographical Regions (North America and Europe): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space. Amongst other elements, the report includes:
Contents
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1. Overview of SARM1
2.2. Role of SARM1 in Neurodegenerative Disorders
2.2.1. Mechanism of Action of SARM1
2.3. Mechanism of SARM1 Pathway Inhibition
2.4. Future Perspectives of SARM1 inhibitors Therapeutics
3. MARKET LANDSCAPE
3.1. SARM1 Inhibitors: Pipeline Review
3.1.1 Analysis by Phase of Development
3.1.2. Analysis by Type of Molecule
3.1.3. Analysis by Phase of Development and Type of Molecule
3.1.4. Analysis by Target Indication
3.1.5. Analysis by Type of Developers
3.1.6. Analysis by Phase of Development and Target Indication
3.2. SARM1 Inhibitors: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Leading Developers: Analysis by Number of Candidates
3.2.4. Regional Landscape by Type of Player
4. COMPANY COMPETITIVENESS ANALYSIS
4.1. Assumptions and Key Parameters
4.2. Methodology
4.3. Company Competitive Analysis: Industry Players
4.4. Company Competitive Analysis: Non-Industry Players
5. COMPANY PROFILES
5.1. Disarm Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Patent Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. Nura Bio
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Patent Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Washington University
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Patent Portfolio
5.3.4. Recent Developments and Future Outlook
6. PUBLICATION ANALYSIS
6.1. Methodology and Parameters
6.2. SARM1 inhibitors Therapeutics: Publication Analysis
6.2.1. Analysis by Year of Publication
6.2.2. Analysis by Type of Publication
6.2.3. Most Popular Journals: Analysis by Number of Publications
6.2.4. Most Popular Journals: Analysis by Journal Impact Factor
6.2.5. Popular Keywords: Analysis by Key Focus Areas
6.2.6. Most Active Publishers: Analysis by Number of Publications
6.2.7. Most Popular Affiliations: Analysis by Number of Publications
6.2.8. Analysis by Geography
7. GRANT ANALYSIS
7.1. Scope and Methodology
7.2. Key Parameters
7.3. SARM1 inhibitors Therapeutics: Grant Analysis
7.3.1. Analysis by Year of Grant Awarded
7.3.2. Analysis by Support Period
7.3.3. Analysis by Amount Awarded
7.3.4. Analysis by Leading Funding Institute Centre
7.3.5. Analysis by Type of Grant
7.3.6. Analysis by Activity Code
7.3.7. Analysis by Study Section Involved
7.3.8. Analysis by Purpose of Grant
7.3.9. Prominent Program Officers: Analysis by Number of Grants
7.3.10. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
7.3.11. Most Popular Departments: Analysis by Number of Grants
7.3.12. Analysis by Location of Recipient
8. PATENT ANALYSIS
8.1. Scope and Methodology
8.2. Key Parameters
8.3. SARM1 inhibitors Therapeutics: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Application Year
8.3.4. Analysis by Geography
8.3.5. Analysis by CPC Symbols
8.3.6. Analysis by Type of Applicant
8.3.7. Analysis by Focus Area
8.3.8. Analysis by Patent Age
8.3.9. Leading Industry Players: Analysis by Number of Patents
8.3.10. Leading Non-Industry Players: Analysis by Number of Patents
8.3.11. Leading Individual Assignees: Analysis by Number of Patents
8.4. SARM1 inhibitors Therapeutics: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. SARM1 inhibitors Therapeutics: Patent Valuation
9. RECENT DEVELOPMENTS
9.1. List of Recent Developments
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Key Parameters and Assumptions
10.2. Methodology
10.3. SARM1 inhibitors Therapeutics: List of Forecasted Drugs
10.4 Global SARM1 inhibitors Therapeutics Market, 2033, 2037 and 2040
10.4.1. SARM1 inhibitors Therapeutics Market: Distribution by Target Indication, 2037 and 2040
10.4.2. SARM1 inhibitors Therapeutics Market: Distribution by Type of Molecule, 2033, 2037 and 2040
10.4.3. SARM1 inhibitors Therapeutics Market: Distribution by Drug Developer, 2037 and 2040
10.4.4. SARM1 inhibitors Therapeutics Market: Distribution by Drug Candidate, 2037 and 2040
10.4.5. SARM1 inhibitors Therapeutics Market: Distribution by Geography, 2037 and 2040
10.5. SARM1 inhibitors Therapeutics Market: Forecast of Individual Product Sales
10.5.1 DSRM-3716 (Disarm Therapeutics): Sales Forecast
10.5.2 Unnamed Molecule 1 (Disarm Therapeutics): Sales Forecast
10.5.3 Unnamed Molecule 2 (Disarm Therapeutics): Sales Forecast
10.5.4 Unnamed Molecule 3 (Disarm Therapeutics): Sales Forecast
10.5.5 Unnamed Molecule (Nura Bio): Sales Forecast
10.5.6 Unnamed Molecule (King’s College London): Sales Forecast
11. APPENDIX 1: LIST OF FIGURES
12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 1.1 Executive Summary: Overall Market Landscape
Figure 1.2 Executive Summary: Patent Analysis
Figure 1.3 Executive Summary: Publication Analysis
Figure 1.4 Executive Summary: Grant Analysis
Figure 1.5 Executive Summary: Company Competitiveness Analysis
Figure 1.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 2.1 Role of SARM1 in Neurodegenerative Disorders
Figure 2.2 Mechanism of SARM1 Pathway Inhibition
Figure 3.1 SARM1 Inhibitors: Distribution by Phase of Development
Figure 3.2 SARM1 Inhibitors: Distribution by Type of Molecule
Figure 3.3 SARM1 Inhibitors: Distribution by Phase of Development and Type of Molecule
Figure 3.4 SARM1 Inhibitors: Distribution by Target Indication
Figure 3.5 SARM1 Inhibitors: Distribution by Type of Developers
Figure 3.6 SARM1 Inhibitors: Distribution by Phase of Development and Target Indication
Figure 3.7 SARM1 Inhibitor Developers: Distribution by Year of Establishment
Figure 3.8 SARM1 Inhibitor Developers: Distribution by Company Size
Figure 3.9 Leading Developers: Distribution by Number of Candidates
Figure 3.10 Regional Landscape by Type of Player
Figure 4.1 Company Competitiveness Analysis: Industry Players
Figure 4.2 Company Competitiveness Analysis: Non-Industry Players
Figure 6.1 Publication Analysis: Distribution by Year of Publication
Figure 6.2 Publication Analysis: Distribution by Type of Publication
Figure 6.3 Most Popular Journals: Distribution by Number of Publications
Figure 6.4 Most Popular Journals: Distribution by Journal Impact Factor
Figure 6.5 Popular Keywords: Analysis by Key Focus Areas
Figure 6.6 Most Active Publishers: Distribution by Number of Publications
Figure 6.7 Most Popular Affiliations: Distribution by Number of Publications
Figure 6.8 Publication Analysis: Distribution by Geography
Figure 7.1 Grant Analysis: Distribution of Year of Grant Awarded
Figure 7.2 Grant Analysis: Distribution by Support Period
Figure 7.3 Grant Analysis: Distribution by Amount Awarded
Figure 7.4 Grant Analysis: Leading Funding Institute Center
Figure 7.5 Grant Analysis: Distribution by Type of Grant
Figure 7.6 Grant Analysis: Distribution by Activity Code
Figure 7.7 Grant Analysis: Distribution by Study Section Involved
Figure 7.8 Grant Analysis: Distribution by Purpose of Grant
Figure 7.9 Grant Analysis: Prominent Program Officers
Figure 7.10 Grant Analysis: Popular Recipient Organizations
Figure 7.11 Grant Analysis: Distribution by Popular NIH Departments
Figure 7.12 Grant Analysis: Distribution by Location of Recipient
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Distribution by Publication Year
Figure 8.3 Patent Analysis: Distribution by Application Year
Figure 8.4 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise and Country-wise)
Figure 8.5 Patent Analysis: Distribution by CPC Symbols
Figure 8.6 Patent Analysis: Distribution by Type of Applicant
Figure 8.7 Patent Analysis: Emerging Focus Area
Figure 8.8 Patent Analysis: Distribution by Patent Age
Figure 8.9 Leading Industry Players: Distribution by Number of Patents
Figure 8.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 8.12 Patent Benchmarking: Distribution by Patent Characteristics (CPC Symbols)
Figure 8.13 Patent Valuation
Figure 10.1 Global SARM1 inhibitors Therapeutics Market, 2033, 2037 and 2040 (USD Million)
Figure 10.2 SARM1 inhibitors Therapeutics Market: Distribution by Target Indication, 2037 and 2040 (USD Million)
Figure 10.3 SARM1 inhibitors Therapeutics Market: Distribution by Type of Molecule, 2033, 2037 and 2040 (USD Million)
Figure 10.4 SARM1 inhibitors Therapeutics Market: Distribution by Drug Developer, 2037 and 2040 (USD Million)
Figure 10.5 SARM1 inhibitors Therapeutics Market: Distribution by Drug Candidate, 2037 and 2040 (USD Million)
Figure 10.6 SARM1 inhibitors Therapeutics Market: Distribution by Geography, 2022 and 2040 (USD Million)
Figure 10.7 DSRM-3716 (Disarm Therapeutics): Sales Forecast, 2022-2040 (USD Million)
Figure 10.8 Unnamed Molecule 1 (Disarm Therapeutics): Sales Forecast, 2022-2040 (USD Million)
Figure 10.9 Unnamed Molecule 2 (Disarm Therapeutics): Sales Forecast, 2022-2040 (USD Million)
Figure 10.10 Unnamed Molecule 3 (Disarm Therapeutics): Sales Forecast, 2022-2040 (USD Million)
Figure 10.11 Unnamed Molecule (Nura Bio): Sales Forecast, 2022-2040 (USD Million)
Figure 10.12 Unnamed Molecule (King’s College London): Sales Forecast, 2022-2040 (USD Million)
Table 3.1 List of SARM1 inhibitors Therapeutics Under Development
Table 3.2 List of SARM1 inhibitors Therapeutic Developers
Table 5.1 Disarm Therapeutics: Product Portfolio
Table 5.2 Disarm Therapeutics: Recent Patent Portfolio
Table 5.3 Disarm Therapeutics: Recent Developments and Future Outlook
Table 5.4 Nura Bio: Product Portfolio
Table 5.5 Nura Bio: Recent Patent Portfolio
Table 5.6 Nura Bio: Recent Developments and Future Outlook
Table 5.7 Washington University: Product Portfolio
Table 5.8 Washington University: Recent Patent Portfolio
Table 5.9 Washington University: Recent Developments and Future Outlook
Table 6.1 SARM1 inhibitors Therapeutics: List of Publications
Table 7.1 SARM1 inhibitors Therapeutics: List of Grants
Table 8.1 SARM1 inhibitors Therapeutics: List of Patents
Table 8.2 SARM1 inhibitors Therapeutics: Rank 1 IP Documents
Table 9.1 SARM1 inhibitors Therapeutics: List of Recent Developments
Table 10.1 SARM1 inhibitors Therapeutics: List of Forecasted Drugs
The following companies / institutes / government bodies and organizations have been mentioned in this report:
Source 1: https://www.sciencedirect.com/science/article/pii/S2451945619303605
Source 2: https://www.nature.com/articles/s41392-020-00311-7